GlassScriptPhysician profile
Meeta Cardon
NPI 1366737256
$18,626.17
in general payments reported to CMS, 2019-2025
26 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $229 · 2021: $33.19 · 2022: $7,079 · 2023: $144 · 2024: $130 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,055 · Travel and Lodging: $1,327 · Honoraria: $1,200 · Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,055.00 |
| Travel and Lodging | $1,326.96 |
| Honoraria | $1,200.00 |
| Food and Beverage | $887.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $15,974.90 | 2022-2025 | Elevidys |
| Catalyst Pharmaceuticals, INC. | $1,325.00 | 2025 | |
| Biogen, INC. | $238.12 | 2019-2020 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $168.42 | 2019-2023 | Zolgensma |
| Novartis Pharmaceuticals Corporation | $137.49 | 2025 | |
| Ptc Therapeutics, INC. | $127.49 | 2019-2020 | |
| Greenwich Biosciences, INC. | $112.39 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $85.61 | 2019-2020 | |
| Ucb, INC. | $64.98 | 2019 | |
| Neos Therapeutics, LP | $58.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.21 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $28.71 | 2019 | |
| Genzyme Corporation | $27.40 | 2019 | |
| Saol Therapeutics INC. | $25.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.95 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $24.16 | 2019 | |
| Upsher-Smith Laboratories LLC | $23.78 | 2020 | |
| Vertical Pharmaceuticals, LLC | $23.02 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.01 | 2020 | |
| Shire North American Group INC | $14.80 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.65 | 2019 | |
| Sk Life Science, INC. | $13.91 | 2021 | |
| Neurelis, INC. | $13.34 | 2020 | |
| Genentech USA, INC. | $13.11 | 2020 | |
| Adlon Therapeutics L.P. | $11.17 | 2019 | |
| Eisai INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meeta Cardon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.